Anixa biosciences receives notice of allowance from u.s. patent and trademark office for car-t technology, further strengthening its robust intellectual property portfolio

San jose, calif. , april 14, 2025 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for a new patent application covering its chimeric antigen receptor-t cell (car-t) technology.
CAR Ratings Summary
CAR Quant Ranking